Compare USNA & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | RZLT |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.1M | 420.8M |
| IPO Year | 1996 | 2011 |
| Metric | USNA | RZLT |
|---|---|---|
| Price | $14.62 | $4.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 81.3K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,060,902,000.00 | N/A |
| Revenue This Year | $3.90 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | $55.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.60 | $1.07 |
| 52 Week High | $32.32 | $11.46 |
| Indicator | USNA | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 26.00 | 49.81 |
| Support Level | N/A | $2.91 |
| Resistance Level | $21.78 | $5.41 |
| Average True Range (ATR) | 1.12 | 0.36 |
| MACD | -0.55 | -0.03 |
| Stochastic Oscillator | 2.25 | 50.60 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.